A US incentive scheme designed to promote the development of antibacterial and antifungal drugs to treat serious or life-threatening infections. It was introduced in the Generating Antibiotic Incentives Now (GAIN) Act in 2012.

QIDP designation confers particular advantages, including priority review by the US Food and Drug Administration (FDA) and fast-track designation, which can accelerate development of a product, as well as an additional five years’ market exclusivity if a product is licensed.